PharmAbcine

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
PharmAbcine is a clinical stage public company in KOSDAQ market(208340) and focusing on next generation therapeutics for cancer patients. Olinvacimab is in several clinical trials globally as single but also combination with Keytruda with MERCK. PMC-309, anti-VISTA neutralizing antibody and PMC-402, anti-TIE2 agonizing antibody are in oncology program and will be in Phase I in 2021.
Ticker:
208340
Exchange:
KOSDAQ
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
Olinvacimab
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
10
Speaker
photo
CEO
PharmAbcine